Management of Chemotherapy-Induced Nausea and Vomiting
-15%
portes grátis
Management of Chemotherapy-Induced Nausea and Vomiting
New Agents and New Uses of Current Agents
Navari, Rudolph M.
Springer International Publishing AG
03/2018
181
Mole
Inglês
9783319800585
15 a 20 dias
454
Descrição não disponível.
1. Introduction.- 2. The Physiology and Pharmacology of Nausea and Vomiting
Induced by Anti-Cancer Chemotherapy in Humans.- 3. First Generation 5HT-3
Receptor Antagonists.- 4. Second Generation Serotonin (5-HT3) Receptor
Antagonist Palonosetron.- 5. The Role of Neurokinin-1 Receptor Antagonists in
CINV.- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting.-
7. Gabapentin for the Prevention of CINV.- 8. Prevention of CINV in Patients Receiving
High-Dose Multiple-Day Chemotherapy.- 9. Clinical Management of CINV.- 10. Treatment
of Chemotherapy-Induced Nausea.- 11. Conclusions.- 12. Future Directions.
Induced by Anti-Cancer Chemotherapy in Humans.- 3. First Generation 5HT-3
Receptor Antagonists.- 4. Second Generation Serotonin (5-HT3) Receptor
Antagonist Palonosetron.- 5. The Role of Neurokinin-1 Receptor Antagonists in
CINV.- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting.-
7. Gabapentin for the Prevention of CINV.- 8. Prevention of CINV in Patients Receiving
High-Dose Multiple-Day Chemotherapy.- 9. Clinical Management of CINV.- 10. Treatment
of Chemotherapy-Induced Nausea.- 11. Conclusions.- 12. Future Directions.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
5-Hyroxytryptamine-3 Receptor Antagonists;Anti-emetics;Dexamethasone;Gabapentin;Multi-day Chemotherapy;Neurokinin-1 Receptor Antagonists;Olanzapine;pharmacotherapy
1. Introduction.- 2. The Physiology and Pharmacology of Nausea and Vomiting
Induced by Anti-Cancer Chemotherapy in Humans.- 3. First Generation 5HT-3
Receptor Antagonists.- 4. Second Generation Serotonin (5-HT3) Receptor
Antagonist Palonosetron.- 5. The Role of Neurokinin-1 Receptor Antagonists in
CINV.- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting.-
7. Gabapentin for the Prevention of CINV.- 8. Prevention of CINV in Patients Receiving
High-Dose Multiple-Day Chemotherapy.- 9. Clinical Management of CINV.- 10. Treatment
of Chemotherapy-Induced Nausea.- 11. Conclusions.- 12. Future Directions.
Induced by Anti-Cancer Chemotherapy in Humans.- 3. First Generation 5HT-3
Receptor Antagonists.- 4. Second Generation Serotonin (5-HT3) Receptor
Antagonist Palonosetron.- 5. The Role of Neurokinin-1 Receptor Antagonists in
CINV.- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting.-
7. Gabapentin for the Prevention of CINV.- 8. Prevention of CINV in Patients Receiving
High-Dose Multiple-Day Chemotherapy.- 9. Clinical Management of CINV.- 10. Treatment
of Chemotherapy-Induced Nausea.- 11. Conclusions.- 12. Future Directions.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
